🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

20 recruiting trials

for Chronic Weight Management

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1) NCT07654361Phase 371 sites📍 Birmingham📍 Birmingham📍 Phoenix Gasherbrum Bio, Inc., a wholly owned subsidiary of Structur… · Tests: Aleniglipron, Placebo A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2) NCT07654374Phase 374 sites📍 Birmingham📍 Chandler📍 Phoenix Gasherbrum Bio, Inc., a wholly owned subsidiary of Structur… · Tests: aleniglipron, aleniglipron, aleniglipron, Placebo A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With Obesity or Overweight NCT07893093Phase 12 sites📍 San Antonio📍 Salt Lake City Ascletis Pharma (China) Co., Limited · Tests: ASC36 Injection A, for subcutaneous use, ASC36 Placebo Injection A, for subcutaneous use, ASC36 Injection B, for subcut… Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2 NCT06396416Phase 41 site📍 London Western University, Canada · Tests: Semaglutide, Virtual Weight Management Coaching Lifestyle Intervention In CKD NCT07633145NA1 site📍 Durham Duke University · Tests: Multi-component lifestyle intervention, Usual Care Control A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight NCT07842640Phase 11 site📍 Baltimore Ascletis Pharma (China) Co., Limited · Tests: ASC35 Injection B, for subcutaneous use, ASC35 Placebo Injection B, for subcutaneous use, Tirzepatide A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects NCT07670884Phase 32 sites📍 Zhengzhou📍 Nanjing Fujian Shengdi Pharmaceutical Co., Ltd. · Tests: HRS9531 Tablet, HRS9531 Tablet Placebo Prescription of Step Counts for Targeted Changes in Body Composition and Cardiometabolic Risk in Overweight/Obese Adults NCT07221279NA1 site📍 Kennesaw Kennesaw State University · Tests: Step counts for predictable changes in body weight/compositon and cardiometabolic risk A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities NCT07743463Phase 3122 sites📍 Birmingham📍 Huntsville📍 Phoenix Ascletis Pharma (China) Co., Limited · Tests: ASC30 tablets A1, Placebo Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) NCT07684144Phase 345 sites📍 Gilbert📍 Canoga Park📍 Cerritos Amgen · Tests: Maridebart Cafraglutide, Placebo Assessment and Management of Multiple Drug Use in Elderly Chronic Disease Patients NCT07180368n/a1 site📍 Xi'an Xijing Hospital DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions NCT07638345NA1 site📍 Seville Adhera Health, Inc. · Tests: Adhera Caring Digital Program-Obesity (ACDP-O) A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight NCT06143956Phase 257 sites📍 Chandler📍 Phoenix📍 Scottsdale Eli Lilly and Company · Tests: LY3305677, LY3841136, Tirzepatide, LY3549492, LY3532226 A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity NCT07792954Phase 334 sites📍 Hefei📍 Beijing📍 Beijing Pfizer · Tests: Berobenatide, Placebo A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes NCT07743450Phase 3135 sites📍 Birmingham📍 Huntsville📍 Peoria Ascletis Pharma (China) Co., Limited · Tests: ASC30 tablets A1, Placebo IVIG vs SCIG in CIDP NCT05584631Phase 11 site📍 New Brunswick Rutgers, The State University of New Jersey · Tests: Intravenous immune globulin G, Subcutaneous immune globulin G A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) NCT06672549Phase 3116 sites📍 Tucson📍 Loma Linda📍 Los Angeles Eli Lilly and Company · Tests: Orforglipron, Placebo Weight Reduction in CLBP NCT04824248NA2 sites📍 Brussels📍 Rotterdam Vrije Universiteit Brussel · Tests: Pain Neuroscience Education, Cognition-targeted exercise therapy, Behavioral weight reduction program Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) NCT07684235Phase 392 sites📍 Anniston📍 Daphne📍 Mobile Amgen · Tests: Maridebart cafraglutide, Placebo A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC36 Tablets for Oral Use in Adult Participants With Obesity or Overweight NCT07893106Phase 11 site📍 South Miami Ascletis Pharma (China) Co., Limited · Tests: ASC36 tablets, for oral use, ASC36 placebo tablets
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy